FasL expression on human nucleus pulposus cells contributes to the immune privilege of intervertebral disc by interacting with immunocytes

International Journal of Medical Sciences

Volumn 10, Issue 8, 2013, Pages 1053-1060

  Liu, Zhi Heng ^a   Sun, Zhen ^a   Wang, Hai Qiang ^a   Ge, Jun ^a   Jiang, Ting Shuai ^a   Chen, Yu Fei ^a   Ma, Ying ^b   Wang, Chen ^b   Hu, Sheng ^b   Samartzis, Dino ^c   Luo, Zhuo Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CD8+ T cell; FasL; Immune privilege; Intervertebral disc degeneration; Macrophage

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

ADULT; APOPTOSIS; ARTICLE; CADAVER DONOR; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL INTERACTION; CELL ISOLATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE PRIVILEGE; IMMUNOREGULATION; INTERVERTEBRAL DISK DEGENERATION; LYMPHOCYTE; MACROPHAGE; MALE; NUCLEUS PULPOSUS; NUCLEUS PULPOSUS CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CD8+ T CELL.; FASL; IMMUNE PRIVILEGE; INTERVERTEBRAL DISC DEGENERATION; MACROPHAGE;

ADULT; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; INTERVERTEBRAL DISC; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 84879390857     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6223     Document Type: Article

References (43)

1. Richardson SM, Mobasheri A, Freemont AJ, Hoyland JA. Intervertebral disc biology, degeneration and novel tissue engineering and regenerative medicine therapies. Histology and histopathology. 2007; 22: 1033-41.
2. Waddell G. Low back pain: a twentieth century health care enigma. Spine. 1996; 21: 2820-5.
3. Stokes IA, Iatridis JC. Mechanical conditions that accelerate intervertebral disc degeneration: overload versus immobilization. Spine. 2004; 29: 2724-32.
4. Jones P, Gardner L, Menage J, Williams GT, Roberts S. Intervertebral disc cells as competent phagocytes in vitro: implications for cell death in disc degeneration. Arthritis research & therapy. 2008; 10: R86. doi:10.1186/ar2466.
5. Tschoeke SK, Hellmuth M, Hostmann A, Robinson Y, Ertel W, Oberholzer A, et al. Apoptosis of human intervertebral discs after trauma compares to degenerated discs involving both receptor-mediated and mitochondrial-dependent pathways. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2008; 26: 999-1006. doi:10.1002/jor.20601.
6. Aladin DM, Cheung KM, Chan D, Yee AF, Jim JJ, Luk KD, et al. Expression of the Trp2 allele of COL9A2 is associated with alterations in the mechanical properties of human intervertebral discs. Spine. 2007; 32: 2820-6. doi:10.1097/BRS.0b013e31815b75c5.
7. Wang HQ, Yu XD, Liu ZH, Cheng X, Samartzis D, Jia LT, et al. Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. The Journal of pathology. 2011; 225: 232-42. doi:10.1002/path.2931.
8. Buckwalter JAMV, Boden SD, Eyre DR, Weidenbaum M. Orthopaedic Basic Science: Biology and Biomechanics of the Musculoskeletal System. Rosemont: American Academy of Orthopaedic Surgeons. 2000.
9. Bobechko WP, Hirsch C. Auto-Immune Response to Nucleus Pulposus in the Rabbit. The Journal of bone and joint surgery British volume. 1965; 47: 574-80.
10. Park JB, Lee JK, Park SJ, Kim KW, Riew KD. Mitochondrial involvement in fas-mediated apoptosis of human lumbar disc cells. The Journal of bone and joint surgery American volume. 2005; 87: 1338-42. doi:10.2106/JBJS.D.02527.
11. Geiss A, Larsson K, Rydevik B, Takahashi I, Olmarker K. Autoimmune properties of nucleus pulposus: an experimental study in pigs. Spine. 2007; 32: 168-73. doi:10.1097/01.brs.0000251651.61844.2d.
12. Lee HO, Ferguson TA. Biology of FasL. Cytokine & growth factor reviews. 2003; 14: 325-35.
13. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270: 1189-92.
14. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 1997; 158: 4122-8.
15. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. The Journal of clinical investigation. 1997; 99: 396-402. doi:10.1172/JCI119173.
16. Swenson KM, Ke B, Wang T, Markowitz JS, Maggard MA, Spear GS, et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation. 1998; 65: 155-60.
17. Takeuchi T, Ueki T, Nishimatsu H, Kajiwara T, Ishida T, Jishage K, et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol. 1999; 162: 518-22.
18. Ke B, Coito AJ, Kato H, Zhai Y, Wang T, Sawitzki B, et al. Fas ligand gene transfer prolongs rat renal allograft survival and down-regulates anti-apoptotic Bag-1 in parallel with enhanced Th2-type cytokine expression. Transplantation. 2000; 69: 1690-4.
19. Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol. 2001; 166: 6914-24.
20. Tourneur L, Malassagne B, Batteux F, Fabre M, Mistou S, Lallemand E, et al. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol. 2001; 167: 1338-46.
21. Park JB, Kim KW, Han CW, Chang H. Expression of Fas receptor on disc cells in herniated lumbar disc tissue. Spine. 2001; 26: 142-6.
22. Takada T, Nishida K, Doita M, Kurosaka M. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine. 2002; 27: 1526-30.
23. Kaneyama S, Nishida K, Takada T, Suzuki T, Shimomura T, Maeno K, et al. Fas ligand expression on human nucleus pulposus cells decreases with disc degeneration processes. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association. 2008; 13: 130-5. doi:10.1007/s00776-007-1204-4.
24. Depraetere V, Golstein P. Fas and other cell death signaling pathways. Seminars in immunology. 1997; 9: 93-107. doi:10.1006/smim.1997.0062.
25. Park JB, Chang H, Kim KW. Expression of Fas ligand and apoptosis of disc cells in herniated lumbar disc tissue. Spine. 2001; 26: 618-21.
26. Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J, Boos N. Magnetic resonance classification of lumbar intervertebral disc degeneration. Spine. 2001; 26: 1873-8.
27. Zhao CQ, Jiang LS, Dai LY. Programmed cell death in intervertebral disc degeneration. Apoptosis: an international journal on programmed cell death. 2006; 11: 2079-88. doi:10.1007/s10495-006-0290-7.
28. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia. 1999; 27: 62-74.
29. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995; 377: 630-2. doi:10.1038/377630a0.
30. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. The Journal of clinical endocrinology and metabolism. 1996; 81: 3119-22.
31. Inui Y, Nishida K, Doita M, Takada T, Miyamoto H, Yoshiya S, et al. Fas-ligand expression on nucleus pulposus begins in developing embryo. Spine. 2004; 29: 2365-9.
32. Olmarker K, Blomquist J, Stromberg J, Nannmark U, Thomsen P, Rydevik B. Inflammatogenic properties of nucleus pulposus. Spine. 1995; 20: 665-9.
33. Satoh K, Konno S, Nishiyama K, Olmarker K, Kikuchi S. Presence and distribution of antigen-antibody complexes in the herniated nucleus pulposus. Spine. 1999; 24: 1980-4.
34. Gertzbein SD, Tile M, Gross A, Falk R. Autoimmunity in degenerative disc disease of the lumbar spine. The Orthopedic clinics of North America. 1975; 6: 67-73.
35. Marshall LL, Trethewie ER, Curtain CC. Chemical radiculitis: A clinical, physiological and immunological study. Clinical orthopaedics and related research. 1977;: 61-7.
36. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA, Jr, et al. The role of Fas in autoimmune diabetes. Cell. 1997; 89: 17-24.
37. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994; 370: 650-2. doi:10.1038/370650a0.
38. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994; 265: 528-30.
39. Theofilopoulos AN, Balderas RS, Gozes Y, Aguado MT, Hang LM, Morrow PR, et al. Association of lpr gene with graft-vs.-host disease-like syndrome. The Journal of experimental medicine. 1985; 162: 1-18.
40. Dittel BN, Merchant RM, Janeway CA, Jr. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 1999; 162: 6392-400.
41. Su X, Hu Q, Kristan JM, Costa C, Shen Y, Gero D, et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. J Immunol. 2000; 164: 2523-32.
42. Nagata S. Apoptosis by death factor. Cell. 1997; 88: 355-65.
43. Nagata S, Golstein P. The Fas death factor. Science. 1995; 267: 1449-56.